One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
ViewRay logo
ViewRay VRAY
report update icon

Quarterly report 2023-Q1
added 05-23-2026

ViewRay Financial Statements 2022-2011 | VRAY

Annual Financial Statements ViewRay

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

477 M 716 M 657 M 318 M 583 M 522 M 209 M 85.4 M - - - -

Shares

181 M 165 M 148 M 102 M 81.1 M 58.5 M 40.1 M 17.4 M 892 K 815 K - -

Historical Prices

2.64 4.35 4.44 3.12 7.19 8.93 5.21 4.9 - - - -

Net Income

-107 M -110 M -108 M -120 M -76.4 M -72.2 M -50.6 M -45 M -33.8 M -27.2 M - -

Revenue

102 M 70.1 M 57 M 87.8 M 81 M 34 M 22.2 M 10.4 M 6.4 M 3.16 M - -

Cost of Revenue

92.2 M 69.8 M 61.1 M 93.3 M 74.4 M 27.7 M 25.9 M 14.5 M 9.15 M 8.19 M - -

Gross Profit

10 M 335 K -4.06 M -5.48 M 6.6 M 6.33 M -3.63 M -4.15 M -2.75 M -5.03 M - -

Operating Income

-107 M -104 M -106 M -121 M -75.1 M -48.2 M -44.2 M -41.4 M -31.6 M -27.1 M - -

Interest Expense

5.06 M 4.24 M 3.31 M 4.33 M 7.7 M 7.25 M 5.95 M 3.45 M 2.24 M 97 K - -

EBITDA

-102 M -97.6 M -99.6 M -116 M -71.7 M -46 M -42.6 M -40.3 M -30.7 M -26 M - -

Operating Expenses

117 M 104 M 102 M 115 M 81.7 M 54.5 M 40.5 M 37.3 M 28.8 M 22.1 M - -

General and Administrative Expenses

52.4 M 56.1 M 61.7 M 65.7 M 50.1 M 31.4 M 23.5 M 21.7 M 14.7 M 9.51 M - -

All numbers in USD currency

Quarterly Income Statement ViewRay

2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

182 M 182 M 181 M 181 M 180 M 179 M 164 M 162 M 160 M 149 M 148 M 148 M 147 M 147 M 99 M 97.6 M 96.7 M 96.3 M 84.9 M 74.5 M 68.9 M 67.7 M 59.1 M 57.2 M 51.8 M 43.6 M 40.2 M 38.2 M 38.2 M 38.2 M 29.2 M 4.34 M 4.34 M 907 K 4.34 M 3.5 M 4.34 M 3.5 M 3.5 M 3.5 M - - - - - - - - -

Net Income

-28.9 M - -26.1 M -27.6 M -25.8 M - -25.3 M -31 M -26.7 M - -28.1 M -26.2 M -27.5 M - -20.8 M -30.8 M -33.4 M - -32.9 M -22 M -4.81 M - -11.2 M -8.35 M -28 M - -14.1 M -12.1 M -13.4 M - -10.3 M -1.61 K -4.11 K - -16.8 K -1.82 K -4.16 K 471 - - - - - - - - - - -

Revenue

22.5 M - 26.5 M 22.1 M 18.9 M - 19.2 M 15 M 15.5 M - 10.1 M 14.2 M 14.2 M - 20.9 M 30.2 M 20.3 M - 17.7 M 16.4 M 26.2 M - 12.2 M 698 K 1.23 M - 357 K 299 K 5.46 M - 5.32 M 182 K 280 K - 2.59 M - - - - - - - - - - - - - -

Cost of Revenue

24 M - 22 M 21.1 M 18.8 M - 17.3 M 16.7 M 15.2 M - 11.2 M 15.3 M 16.4 M - 20.3 M 26.9 M 25.6 M - 17.3 M 16.4 M 20.6 M - 10.2 M 826 K 1.04 M - 1.18 M 863 K 6.53 M - 6.09 M 833 K 777 K - 2.91 M - - - - - - - - - - - - - -

Gross Profit

-1.43 M - 4.45 M 1.09 M 94 K - 1.89 M -1.67 M 322 K - -1.06 M -1.04 M -2.11 M - 574 K 3.25 M -5.36 M - 364 K 69 K 5.57 M - 1.98 M -128 K 185 K - -826 K -564 K -1.07 M - -775 K -651 K -497 K - -317 K - - - - - - - - - - - - - -

Operating Income

-29.6 M - -23.9 M -29.8 M -27.5 M - -23.3 M -26.5 M -24.7 M - -25 M -25.6 M -30.1 M - -31.7 M -26.3 M -30.4 M - -24.1 M -18.2 M -11.3 M - -11.6 M -12.7 M -11 M - -10.9 M -10.7 M -12.1 M - -9.08 M -11.3 M -4.11 K - -16.8 K -1.82 K -4.16 K 471 - - - - - - - - - - -

Interest Expense

2.63 M - 1.51 M 192 K 1.06 M - 1.06 M 1.06 M 1.06 M - 1.07 M 1.07 M 1.04 M - 1.07 M 1.07 M 759 K - 1.97 M 1.92 M 1.87 M - 1.84 M 1.79 M 1.74 M - 1.71 M 1.38 M 1.08 M - 1.05 M 839 K 484 K - 525 K - - - - - - - - - - - - - -

EBITDA

-28.7 M - -20.1 M -27.1 M -26.2 M - -18.6 M -24.9 M -23.1 M - -23.6 M -24.1 M -28.6 M - -30.5 M -25.2 M -29.5 M - -23.2 M -17.3 M -10.6 M - -11.1 M -12.2 M -10.5 M - -10.4 M -10.3 M -11.7 M - -8.8 M -11 M 242 K - 190 K -1.82 K -4.16 K 471 - - - - - - - - - - -

Operating Expenses

28.2 M - 28.4 M 30.9 M 27.6 M - 25.2 M 24.8 M 25 M - 23.9 M 24.5 M 27.9 M - 32.3 M 29.5 M 25 M - 24.5 M 18.3 M 16.9 M - 13.6 M 12.6 M 11.1 M - 10.1 M 10.2 M 11 M - 8.31 M 10.7 M 4.11 K - 16.8 K 1.82 K 4.16 K 471 - - - - - - - - - - -

General and Administrative Expenses

11.6 M - 12.9 M 13.1 M 12.8 M - 12.5 M 13.9 M 15.6 M - 16 M 15.2 M 15.8 M - 19.4 M 15.4 M 15.1 M - 16.7 M 10.5 M 9.85 M - 7.5 M 7.46 M 7.15 M - 5.83 M 5.79 M 6.32 M - 4.28 M 1.61 K 4.32 M - 3.48 M 1.82 K 4.16 K 471 - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements ViewRay VRAY
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting ViewRay plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 105.14 -0.28 % $ 61.5 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
Smith & Nephew plc Smith & Nephew plc
SNN
$ 30.34 -0.57 % $ 26.3 B britainBritain
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
Penumbra Penumbra
PEN
$ 320.36 0.39 % $ 12.5 B usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Viemed Healthcare Viemed Healthcare
VMD
$ 8.81 -2.87 % $ 343 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 139.95 -3.71 % $ 9.85 B usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
TELA Bio TELA Bio
TELA
$ 0.78 2.43 % $ 36.6 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
TransMedics Group TransMedics Group
TMDX
$ 96.58 2.84 % $ 3.28 B usaUSA
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Butterfly Network Butterfly Network
BFLY
$ 6.11 6.0 % $ 1.51 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Zimmer Biomet Holdings Zimmer Biomet Holdings
ZBH
$ 103.42 1.3 % $ 20.5 B usaUSA
Abbott Laboratories Abbott Laboratories
ABT
$ 104.47 -0.23 % $ 182 B usaUSA
Align Technology Align Technology
ALGN
$ 163.89 0.26 % $ 11.9 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
$ 7.08 1.95 % $ 1.06 B usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
$ 43.66 1.45 % $ 64.6 B usaUSA
Cognyte Software Ltd. Cognyte Software Ltd.
CGNT
$ 7.93 1.34 % $ 578 M israelIsrael
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 -0.59 % $ 3.4 M usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
$ 369.72 3.22 % $ 10.1 B usaUSA